VOR · Vor Biopharma Inc. · Executive Compensation
$19.90
+0.77 (+4.03%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$1.18B
Shares
59.16M
Volume · Oct 9
1.1M
Avg daily vol (3M)
991.52K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jean-Paul Kress | President, Chief Executive Officer and Chairman | $65,027,569 |
| Sandesh Mahatme | Chief Financial Officer | $39,406,098 |
| Qing Zuraw | Former Chief Development Officer | $11,837,193 |
| Robert Ang | Former President and Chief Executive Officer | $3,364,395 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Ang | M.B.B.S. Former President and Chief Executive Officer | $2,220,349 |
| Eyal Attar | Former Chief Medical Officer | $1,075,785 |
| Tirtha Chakraborty | Former Chief Scientific Officer and Head of Technical Operations | $1,003,852 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Ang | M.B.B.S. Former President and Chief Executive Officer | $2,691,044 |
| Eyal Attar | Former Chief Medical Officer | $1,400,120 |
| Tirtha Chakraborty | Former Chief Scientific Officer and Head of Technical Operations | $1,309,944 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Ang | M.B.B.S. President and Chief Executive Officer | $4,521,278 |
| Nathan Jorgensen | Ph.D., M.B.A. Chief Financial Officer | $2,167,189 |
| Tirtha Chakraborty | Chief Scientific Officer | $1,892,985 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Ang | M.B.B.S. President and Chief Executive Officer | $1,663,537 |
| Christopher Slapak | Chief Medical Officer | $590,648 |
| Tirtha Chakraborty | Chief Scientific Officer | $540,638 |
| Nathan Jorgensen | Ph.D., M.B.A. Chief Financial Officer | $539,367 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Ang | M.B.B.S. President and Chief Executive Officer | $2,754,744 |
| Christopher Slapak | Chief Medical Officer | $1,224,346 |
| Tirtha Chakraborty | Chief Scientific Officer | $1,177,890 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| David Zaccardelli, Pharm.D. | independent Class II director | Appointed | 2026-07-07 |
| Andrew Levin, M.D., Ph.D. | member of the Board of Directors | Resigned | 2026-07-07 |
| Dr. Qing Zuraw | Chief Development Officer | Terminated | 2026-01-02 |
| Wouter Joustra | Class III director | Appointed | 2025-12-18 |
| Wouter Joustra | independent Class III director | Appointed | 2025-12-18 |
| Andrew Levin | independent Class II director | Appointed | 2025-12-18 |
| Sarah Reed | member of the Company's Board of Directors | Resigned | 2025-12-18 |
| Jeremy Sokolove | Chief Medical Officer | Appointed | 2025-11-03 |
| Sarah Reed | independent Class II director | Appointed | 2025-08-27 |
| Matthew Patterson | Director | Resigned | 2025-08-27 |
| David Lubner | Director | Resigned | 2025-08-27 |
| Joshua Resnick, M.D. | Director | Resigned | 2025-08-27 |
| Michel Detheux | independent Class I director | Appointed | 2025-07-22 |
| Alexander (Bo) Cumbo | independent Class I director | Appointed | 2025-07-22 |
| Qing Zuraw | Chief Development Officer | Appointed | 2025-07-22 |
| Sven (Bill) Ante Lundberg | member of the Board of Directors | Resigned | 2025-07-22 |
| Sandy Mahatme | Chief Business Officer | Appointed | 2025-07-10 |
| Sandy Mahatme | Chief Financial Officer | Appointed | 2025-07-10 |
| Sandesh Mahatme | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | Appointed | 2025-07-10 |
| Jean-Paul Kress, M.D. | Chairman of the Board | Appointed | 2025-06-26 |
| Jean-Paul Kress, M.D. | Chief Executive Officer | Appointed | 2025-06-26 |
| Jean-Paul Kress | Director | Appointed | 2025-06-26 |
| Jean-Paul Kress | Chairman of the Board | Appointed | 2025-06-26 |
| Jean-Paul Kress | President | Appointed | 2025-06-26 |
| Jean-Paul Kress | Chief Executive Officer | Appointed | 2025-06-26 |